Participant baseline characteristics
| Characteristics | Participants (n=899) |
| Gender, n (%) | |
| Female | 609 (68) |
| Male | 277 (31) |
| Prefer not to say | 6 (0.7) |
| Missing | 7 (0.8) |
| Age, n (%) | |
| 18–24 | 76 (8) |
| 25–44 | 323 (36) |
| 45–64 | 375 (42) |
| 65+ | 118 (13) |
| Prefer not to say | 7 (0.8) |
| Medical conditions, n (%) | |
| Crohn’s disease and ulcerative colitis | 376 (42) |
| Rheumatoid arthritis and juvenile idiopathic arthritis | 227 (25) |
| Axial spondyloarthritis including ankylosing spondylitis | 170 (19) |
| Skin psoriasis and psoriatic arthritis | 112 (13) |
| Others | 11 (1) |
| Missing | 3 (0.3) |
| Period of Humira use before switching, n (%) | |
| Less than 1 year | 204 (23) |
| More than 1–5 years | 468 (52) |
| More than 5 years | 227 (25) |
| Patient-assessed disease activity prior to switch, n (%) | |
| Very well controlled | 564 (63) |
| Controlled well | 225 (25) |
| Neither | 85 (9) |
| Not controlled | 12 (1) |
| Not controlled well at all | 10 (1) |
| Not applicable | 3 (0.3) |
| No of the new biosimilar injections before survey, n (%) | |
| 1 | 92 (10) |
| 2–4 | 318 (35) |
| 5–10 | 372 (41) |
| More than 10 | 110 (12) |
| Missing | 7 (0.8) |
| Biosimilar, n (%) | |
| Imraldi | 561 (62) |
| Amgevita | 237 (26) |
| Hyrimoz | 56 (6) |
| Don’t know/not sure | 45 (5) |
Values presented as n (%).